Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3042% above fair value

$305.23−0.45 (-0.15%)

Close on Nov 13, 2026Market cap $9.03BP/E 41.4Yield –

Krystal Biotech gross margin

Gross margin is gross profit as a percentage of revenue.

Krystal Biotech has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Krystal Biotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KRYS.

Revenue growth26.0% · median 55.8%

Operating margin48.4% · median -18.4%

Net margin47.9% · median -22.4%

Advertisement
300 × 250

See a number that looks wrong?